Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Registry of Fosaprepitant Dimeglumine for Chemotherapy-Induced Nausea and Vomiting
ChiCTR2000039884Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Complete response rate (CR). Started Jul 2020; status: recruiting.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2000039884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039884.